Autologous Blood Injection for Treatment of Achilles Tendinopathy? A Randomised Controlled Trial

Phase 2

Completed

• Conditions: Achilles tendinopathy; Physical Medicine / Rehabilitation - Other physical medicine / rehabilitation; Musculoskeletal - Other muscular and skeletal disorders

• Registration Number: ACTRN12610001020077
• Lead Sponsor: Jake Pearson

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-11-22
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Diagnosis of mid achilles tendinopathy (activity-related pain of gradual or semi-acute onset, post-inactivity stiffness, and tenderness, swelling and nodularity localised to the mid-tendon) with duration of symptoms of at least three months.

Exclusion Criteria

Diagnostic uncertainty or concurrent presence of insertional pathology,
Anticoagulant therapy,
Systemic disease that may contribute to pathology,
Elite level sportsperson, or
Having received any injection therapy for the tendon within the last three months.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Victorian Institute of Sport Assessment for Achilles (VISA-A) score[Baseline, 6 weeks and 12 weeks]

Secondary Outcome Measures

Name	Time	Method
the treatment group was asked to rate the degree of discomfort experienced<br><br>a) during the injection procedure (no significant discomfort, mild discomfort, moderate discomfort, or severe pain) and<br><br>b) over the 48 hours following injection, relative to pre-injection (improved, no change, mild discomfort, moderate discomfort, or severe pain).[As above<br><br>a) during the injection and<br><br>b) on average over the 48 hours following injection compared to before the injection]